

DR SAMIRA ALLIOUACHENE (Orcid ID : 0000-0002-0998-8997)

Article type : O - Original Article

Uninephrectomy and class II PI3K-C2 β inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice

Samira Alliouachene,¹ Julius E Kieswich,¹ Benoit Bilanges,² Kieran McCafferty,¹

Christoph Thiemermann,¹ Bart Vanhaesebroeck,² Muhammad M Yaqoob¹

¹Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom

²UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, United Kingdom

Correspondence

Samira Alliouachene

Email: samira.alliouachene@qmul.ac.uk

Muhammad M Yaqoob

Email: m.m.yaqoob@qmul.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/AJT.16470](https://doi.org/10.1111/AJT.16470)

This article is protected by copyright. All rights reserved

Abbreviations:

CKD	Chronic kidney disease
DKD	Diabetes kidney disease
FAS	Fatty acid synthase
FGF21	Fibroblast growth factor 21
FGFR1	Fibroblast growth factor receptor 1
GFR	Glomerular filtration rate
G6Pase	Glucose 6 phosphatase
HFD	High fat diet
KI	Knock-in
NCD	Normal chow diet
PI3K-C2 β	Phosphoinositide 3-kinase-C2 β
UNx	Uninephrectomy
WAT	White adipose tissue

Abstract

Uninephrectomy (UNx) in living kidney donors for transplantation is now routine clinical practice. While chronic kidney disease, due to bilateral kidney dysfunction, is associated with insulin resistance, liver steatosis and type 2 diabetes, the metabolic impact of UNx remains unclear. To better understand the crosstalk between the kidney and insulin target tissues, we studied the metabolic consequences of UNx and the potential involvement of class II PI3K-C2 β , the inactivation of which has been reported to result in insulin sensitization. Mice underwent UNx or sham operation followed by either normal chow or high fat diet (HFD). Seventeen weeks post UNx, mice showed improved glucose tolerance, insulin sensitivity and decreased HFD-induced liver steatosis. This was associated with an enhanced serum FGF21 and insulin-stimulated Akt signaling in the liver and muscle of both lean and obese mice. Remarkably, the combination of UNx and PI3K-C2 β inactivation protected against HFD-induced obesity and further potentiated the metabolic improvement observed in WT UNx mice correlating with a synergistic increase in metabolic tissues of (1) insulin-stimulated Akt signaling (2) FGFR1 and β Klotho expression. We demonstrated a potential beneficial effect of kidney donation and more effectively with PI3K-C2 β inactivation to protect against metabolic disorders through a mutual insulin/FGF21 sensitization.

1-Introduction

The kidney is an important organ contributing to glucose homeostasis. Thus most of CKD patients, with bilateral kidney dysfunction, develop metabolic disorders such as insulin resistance, type 2 diabetes and liver steatosis leading to cardiovascular disease and increased mortality¹⁻⁵. These observations led clinicians to question the safety of living kidney donation for transplantation which is currently the best treatment for patients suffering from end-stage renal disease. A major concern regarding the use of living donors is whether UNx predisposes the donor to develop CKD and metabolic disorders. Despite numerous experimental and clinical studies documenting the metabolic consequences of a kidney donation through UNx, only few and conflicting data have been reported⁶⁻¹⁴. Several recent clinical studies performed on living kidney donors have suggested that kidney donation may result in insulin resistance and type 2 diabetes even independently of changes in glomerular filtration rate (GFR)^{6, 7}. In contrast, other clinical studies indicated that the risk factors for the development of diabetes after donation are similar to what is seen in the general population^{11, 14}. Moreover a recent clinical meta-analysis found that donors had no increased risk of developing diabetes¹³. Experimental studies on rats showed that UNx leads to kidney injury together with glucose intolerance, insulin resistance and dyslipidemia from 6 months post surgery^{9, 10}. Conversely, others have reported a beneficial effect of UNx in rats from 13 weeks post surgery, with a lower basal glycemia and an increase in insulin sensitivity despite a mild decrease in renal function¹⁵. Moreover a recent study in mice showed no differences in glucose tolerance or insulin sensitivity even 4 months post UNx and reported an unexpected opposite effect on liver and skeletal muscle in obese mice, whereby UNx protected HFD-fed mice from hepatic insulin resistance and steatosis but led to skeletal muscle insulin resistance¹⁶. Despite all these studies, the metabolic consequences of UNx are still unclear and systemic insulin signaling in insulin target tissues (liver, muscle and adipose tissue) post UNx remain to be investigated. Therefore it remains critical to investigate the effect of UNx on glucose homeostasis and systemic insulin signaling and gain more understanding on the crosstalk between the kidney and insulin target tissues.

FGF21 serum concentrations have been shown to be elevated in kidney donors post UNx suggesting renal excretion as a major route for FGF21 elimination and making this endocrine/paracrine factor an attractive candidate to play a role in the crosstalk between the kidney and insulin target tissues¹⁷. Recently FGF21 has emerged as an important metabolic regulator having a favorable effect on glucose and lipid metabolism¹⁸⁻²¹. FGF21 is mainly produced by the liver and initiates its action by activating a unique dual receptor complex consisting of a co-receptor β klotho and the tyrosine kinase FGF receptor 1 (FGFR1)²¹.

Transgenic mice overexpressing FGF21 or pharmacological administration of FGF21 in mice induces Akt phosphorylation in metabolic organs, improves insulin sensitivity and protects against HFD-induced obesity, insulin resistance and liver steatosis²². The crosstalk between FGF21 and insulin sensitivity is further supported by recent multiple reports demonstrating a synergy between FGF21 and insulin through a mutual sensitization to synergistically increase Akt signaling and regulate glucose and lipid metabolism in cell culture, animals and humans^{20, 23-25}. Conversely, although FGF21 performs several beneficial functions, its serum level is known to be paradoxically elevated in several metabolic disorders, such as obesity, insulin resistance and liver steatosis suggesting a potential FGF21-resistant state²⁶⁻²⁸. In support of this hypothesis, mRNA expression and activity of FGFR1 has been shown to be reduced in liver and white adipose tissue (WAT) in both obese and diabetic mice.

In the present study, we first addressed the impact of UNx on whole-body glucose homeostasis and systemic insulin signaling in mice. In order to gain more understanding on the crosstalk between the kidney and insulin target tissues, we also explored the possible implication of the class II PI3K-C2 β isoform for several reasons. First, PI3K-C2 β gene expression has been found up-regulated in kidneys of diabetic nephropathy patients²⁹. Second, this lipid kinase plays an important role in insulin signaling and it has been reported that its inactivation increased insulin sensitivity and protects against HFD-induced liver steatosis in mice³⁰. Altogether, this suggested a potential role of PI3K-C2 β in the crosstalk between the kidney and insulin target tissues to regulate glucose metabolism in UNx context. To assess the role of PI3K-C2 β after UNx, we performed UNx in PI3K-C2 β kinase-dead knock-in mice³⁰; (further referred to as C2 β ^{D1212A/D1212A} mice) as a model to mimic the impact of a pharmacological PI3K-C2 β inhibitor. Because of the high probability of developing obesity with age after kidney donation, we investigated both lean and obese mice and used HFD mice as an obesity mouse model.

2-Methods

Mice

All animal experiments were conducted in accordance with the United Kingdom Home Office Animals 1986 Scientific Procedures. All experiments were performed on 7-week-old male C57BL/6J mice. Mice were kept on standard chow diet (20% protein, 75% carbohydrate, 5% fat) on a 12 h light-dark cycle, with free access to water in individually-ventilated cages. For HFD experiments, mice were maintained on diet 824053 from Special Diet Services Inc. (20% protein, 35% carbohydrate and 45% fat) for 16 weeks. Mice underwent UNx or

sham-operation at 7-weeks of age. Left nephrectomy was performed following an incision on the left dorsolateral paralumbar region. Sham-operated control mice underwent identical procedure except for kidney removal. The mice were monitored until they recovered from anaesthesia. A week after UNx mice were given high fat diet for 16 weeks. PI3K-C2 β kinase-dead knock-in mice (C2 β ^{D1212A/D1212A} mice) have been reported earlier³⁰.

Metabolic Analysis

Oral glucose tolerance test and insulin tolerance test were performed at 13 and 15 weeks post UNx respectively. The procedure was described in supplemental material. *In vivo* insulin stimulation was performed as already described³⁰. Serum levels of insulin, IGF1, leptin, triglyceride, cholesterol, adiponectin and FGF-21 were measured by ELISA and colorimetric kit (Alpha diagnostic for insulin, Thermofisher for IGF-1, Millipore for leptin and adiponectin; Cayman Chemical Company for Triglyceride and cholesterol; R&D System for FGF-21). Triglyceride levels in liver tissue were determined by ELISA (Abcam).

Western Blot Analysis

Procedure as been described earlier³⁰. All antibodies were against mouse proteins as follows: pAkt-S473, total Akt, FAS, FGFR1 (Cell Signaling Technology) all used at 1:1000 dilution, G6Pase (Santa Cruz) used at 1:500 dilution and α -tubulin (Sigma) used at 1:5000 dilution .

Histology

Procedure has been described earlier³⁰.

RNA extraction, cDNA synthesis and quantitative RT PCR

20mg of liver and 80mg of WAT tissue was used for RNA extraction using the Qiagen RNeasy[®] Fibrous Tissue Mini Kit (Qiagen) for the liver and Qiagen RNeasy[®] Lipid Tissue Mini Kit (Qiagen) for the WAT. 500ng of extracted RNA was used for the reverse transcription using a superscript first-strand synthesis kit (RT2 First Strand Kit (Qiagen). Real time PCR reactions were preformed using SYBR Green master mix (Qiagen) using 5 ng of cDNA. See the primers used in supplemental material.

Statistical Analysis

All data are shown as mean \pm SEM. Data sets were compared for statistical significance using a two-tailed Student's t-test. All statistical analyses were generated using Excel software and statistical significance indicated as: * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

3-Results

Combination of UNx and PI3K-C2 β inactivation decreases HFD-induced obesity

We first investigated the impact of UNx and PI3K-C2 β inactivation on body weight under both NCD and HFD. Under NCD, body weight gain was not affected either by UNx or/and PI3K-C2 β inactivation (Figure 1A). However under HFD, while WT UNx-operated and C2 $\beta^{D1212A/D1212A}$ mice showed a similar body weight gain compared to WT sham-operated mice, C2 $\beta^{D1212A/D1212A}$ UNx-operated mice showed a synergistic reduction in body weight compared to WT UNx-operated or C2 $\beta^{D1212A/D1212A}$ mice ($p < 0.05$ and $p < 0.01$ respectively; AUC graph). Thus C2 $\beta^{D1212A/D1212A}$ UNx-operated mice had a 17% reduction in body weight compared to WT sham-operated mice (Figure 1B; $p < 0.001$; AUC graph).

This decrease in body weight was not due to a decrease in food intake between WT and C2 $\beta^{D1212A/D1212A}$ mice under any condition tested (Figure S1). Moreover, we have not observed an effect of UNx on PI3K-C2 β mRNA or protein expression (Figure S2).

UNx and PI3K-C2 β inactivation synergistically protect against HFD-induced insulin resistance

While CKD results in multiple metabolic derangements, the metabolic impact of UNx remains largely unclear. Therefore, we next studied the effect of UNx on glucose metabolism and insulin sensitivity. Under both NCD and HFD, fasting blood glucose, insulin and IGF-1 levels were not affected either by UNx or/and PI3K-C2 β inactivation (Figure 2A-B; Figure S3). Surprisingly in both WT lean and obese mice, UNx significantly improved glucose tolerance (Figure 2C-D; $p < 0.05$; AUC graph) and insulin sensitivity (Figure 2E-F; $p < 0.01$; AUC graph), highlighting a beneficial effect of UNx on glucose metabolism and insulin sensitivity. Interestingly, PI3K-C2 β inactivation, which has been previously shown to increase glucose tolerance and insulin sensitivity, did not further improve UNx-induced positive impact on glucose tolerance under both NCD and HFD, and insulin sensitivity under NCD (Figure 2C-E) but accentuated the UNx-induced positive impact on insulin sensitivity under HFD only (Figure 2F; $p < 0.01$; AUC graph).

UNx and PI3K-C2 β inactivation synergistically protect against HFD-induced liver steatosis

With accumulating evidence demonstrating a link between CKD and hepatic steatosis and dyslipidemia³¹⁻³³, we investigated the impact of UNx on lipid metabolism and the development of liver steatosis. Therefore we analysed liver histology and lipid profile in mice after UNx and PI3K-C2 β inactivation. When fed NCD, liver weight was not affected either by UNx or/and PI3K-C2 β inactivation (Figure 3A). However, under conditions

of obesity, UNx induced a 40% reduction in liver weight compared to sham-operated mice (Figure 3A; $p < 0.001$). Interestingly liver from $C2\beta^{D1212A/D1212A}$ mice showed a similar weight reduction under both sham and UNx conditions (Figure 3A; $p < 0.001$).

Histological examination of liver sections revealed no apparent differences in all groups under NCD (Figure 3B). However in conditions of obesity, both WT UNx-operated and $C2\beta^{D1212A/D1212A}$ mice showed a 45% reduction in liver steatosis compared to sham-operated mice (as assessed by the presence of vacuoles) (Figure 3B; $p < 0.01$). Interestingly, $C2\beta^{D1212A/D1212A}$ UNx-operated mice were further protected against HFD-induced liver steatosis compared to WT UNx-operated and $C2\beta^{D1212A/D1212A}$ mice (Figure 3B; $p < 0.01$) and were almost completely protected against HFD-induced liver steatosis compared to control group, with a 80% reduction of hepatic lipid accumulation (Figure 3B; $p < 0.001$). This was correlated with a significant reduction in levels of triglycerides in the liver of $C2\beta^{D1212A/D1212A}$ UNx-operated mice compared to WT sham and UNx-operated mice (Figure 3C; $p < 0.01$ and $p < 0.05$ respectively). However serum triglyceride levels did not differ between all groups in both NCD and HFD (Figure S4A). Only serum cholesterol levels were found to be decreased in $C2\beta^{D1212A/D1212A}$ UNx-operated mice compared to WT sham and UNx-operated animals (Figure S4B; $p < 0.05$). Adipokine levels such as leptin and adiponectin implicated in protecting from hepatic steatosis and lipid accumulation were unchanged in all conditions (Figure S4C-D). Correlating with the previous data, under HFD, while hepatic fatty acid synthase (FAS) and glucose 6-phosphatase (G6Pase) expression was similar in both UNx-operated and $C2\beta^{D1212A/D1212A}$ mice compared to control animals, we observed a significant downregulation of FAS and glucose G6Pase expression in $C2\beta^{D1212A/D1212A}$ UNx-operated mice, showing that UNx and PI3K-C2 β inactivation combination induced a significant decrease in hepatic lipogenesis and gluconeogenesis (Figure 3D; $p < 0.05$).

Combination of UNx and PI3K-C2 β inactivation increases FGF21 responsiveness

We hypothesized that FGF21 could be an interesting candidate as it has been shown to be elevated in kidney donors and has recently emerged as a beneficial factor to increase insulin sensitivity¹⁷⁻²¹. Therefore we measured serum FGF21 levels after UNx and PI3K-C2 β inactivation. As previously observed in humans, we observed an increase in fasted serum FGF21 levels in UNx-operated animals compared to sham controls in both NCD and HFD conditions (Figure 4A; $p < 0.05$ under NCD and $p < 0.01$ under HFD). Next we investigated whether FGF21 serum levels were also affected in $C2\beta^{D1212A/D1212A}$ mice, which are as insulin sensitive as UNx-operated mice and surprisingly, unlike UNx-operated mice, $C2\beta^{D1212A/D1212A}$ animals showed decreased serum

FGF21 levels under HFD and more significantly under NCD condition, suggesting a potentially enhanced FGF21 sensitivity upon PI3K-C2 β inactivation (Figure 4A; $p < 0.01$). Interestingly, under HFD, serum FGF21 levels in C2 $\beta^{D1212A/D1212A}$ UNx-operated mice were similar to Unx-operated animals and remained higher compared to sham-operated mice (Figure 4A; $p < 0.01$). Because the elevation in circulating FGF21 levels can be explained not only by its decreased renal clearance, but also by enhanced FGF21 expression and secretion, therefore we assessed the impact of UNx and PI3K-C2 β inactivation on FGF21 mRNA expression in the liver, which is the primary organ for production of circulating FGF21. Correlated with serum FGF21 levels, hepatic FGF21 mRNA expression was markedly higher in UNx-operated mice and lower in C2 $\beta^{D1212A/D1212A}$ mice compare to WT sham mice (Figure 4B; $p < 0.05$) suggesting an opposite impact of UNx and PI3K-C2 β inactivation on FGF21 responsiveness. However, hepatic FGF21 expression of C2 $\beta^{D1212A/D1212A}$ UNx-operated mice was lower compared to UNx-operated animals and was comparable to sham operated mice (Figure 4B; $p < 0.05$).

Recently, extensive crosstalk between FGF21 and insulin sensitivity has been reported, demonstrating mutual sensitization between these growth factors to regulate glucose and lipid metabolism^{20, 23, 24}. These observation led us to speculate that UNx and PI3K-C2 β inactivation induced-insulin sensitization could increase FGF21 responsiveness^{20, 23-25}. We therefore investigated the impact of UNx and PI3K-C2 β inactivation on expression of FGFR1 and its co receptor β klotho in the liver and WAT which are two major targets of FGF21 (Figure 4C-D). We showed that FGFR1 protein expression was slightly increased in either WT UNx-operated or C2 $\beta^{D1212A/D1212A}$ animals and further increased in C2 $\beta^{D1212A/D1212A}$ UNx-operated group compared to WT UNx-operated animals in both liver and WAT (Figure 4C; $p = 0.068$ in liver and $p < 0.05$ in WAT). Similarly to FGFR1, we found that β klotho mRNA expression was also upregulated in UNx-operated or C2 $\beta^{D1212A/D1212A}$ animals which was further increased in C2 $\beta^{D1212A/D1212A}$ UNx operated mice compared to WT UNx-operated liver and WAT (Figure 4D; $p < 0.001$ in liver and $p < 0.05$ in WAT).

UNx and PI3K-C2 β inactivation synergistically enhance insulin-stimulated Akt signaling in metabolic tissues

Several reports have demonstrated a synergy between insulin and FGF21 to regulate glucose and lipid metabolism via a synergistic increase in Akt signaling^{20, 23-25}. To investigate if this also occurs upon combined UNx and PI3K-C2 β inactivation, we examined the impact of UNx and PI3K-C2 β inactivation on Akt signaling pathway in metabolic tissues (liver, muscle and WAT) with Akt phosphorylation being a readout for insulin sensitivity. Compared to sham-operated mice, *in vivo* insulin stimulation of UNx-operated mice led to enhanced Akt phosphorylation in the liver and muscle under NCD (Figure 5A-C; $p < 0.05$) and in the liver under

HFD conditions (Figure 5D; $p < 0.05$), correlating with the improved insulin sensitivity observed in UNx mice *in vivo*. When UNx was combined with PI3K-C2 β inactivation, the inhibition of which has been reported to result in enhanced insulin-stimulated Akt signaling, we observed a remarkable synergistic enhancement of insulin-induced Akt phosphorylation in the muscle of lean mice and more significantly in the liver and muscle of obese mice compared to groups with Unx or PI3K-C2 β inactivation alone (Figure 5; $p < 0.05$ in liver and $p < 0.01$ in muscle).

4-Discussion

Living kidney donation for transplantation is currently the optimal treatment for the ever-increasing number of patients suffering from end-stage renal disease. Therefore it is imperative to increase our knowledge on the short- and long-term risks involved in kidney donation. Most CKD patients, with bilateral renal dysfunction, develop insulin resistance, type 2 diabetes and liver steatosis leading to cardiovascular disease and increased mortality¹⁻³. While CKD patients develop metabolic disorders, the metabolic impact of kidney donation through UNx remains unclear. Despite numerous experimental and clinical studies documenting the metabolic consequences of UNx so far conflicting data have been published⁶⁻¹³. Therefore it remains critical to investigate the effect of UNx on glucose homeostasis, systemic insulin signaling in insulin target tissues and gain more understanding on the crosstalk between the kidney and insulin target tissues. In the present study we investigated the impact of UNx on whole-body glucose homeostasis together with a systemic insulin signaling analysis in both lean and obese mice using UNx mouse model. UNx in rodents is an ideal model to study the metabolic effects of reduced renal function and mimic the clinical situation of kidney donation^{6, 34, 35}.

Surprisingly, our data showed an improved glucose tolerance and insulin sensitivity in UNx animals fed on both NCD and HFD with a decrease of HFD-induced liver steatosis. This correlated with a significant increase in serum FGF21 and *in vivo* insulin stimulated-Akt signaling in metabolic tissues (particularly in liver and muscle). Remarkably, the combination of UNx and PI3K-C2 β inactivation protected against HFD-induced obesity and further potentiated the metabolic improvement observed in WT UNx mice. Moreover, combined UNx and PI3K-C2 β inactivation induced a synergistic inhibition of hepatic lipogenesis and gluconeogenesis with the decrease of fatty acid synthase and glucose 6-phosphatase expression. This metabolic improvement correlated with a synergistic increase in metabolic tissues of (1) insulin-stimulated Akt signaling and (2) FGFR1 and β Klotho expression, suggesting an increased sensitization to FGF21. This study highlights a beneficial

effect of UNx alone and more effectively in combination with PI3K-C2 β inhibition to protect kidney donors against obesity, insulin resistance and liver steatosis through a mutual insulin and FGF21 sensitization.

Our findings are in contrast to some of previous experimental studies on mice and rats and clinical reports from living kidney donors showing that UNx correlates with insulin resistance and diabetes ^{4, 7, 9, 10}. One of the reasons for such discrepancies could be the length of the starvation period prior to metabolic studies. Indeed inconsistencies with respect to fasting duration have been previously reported to alter insulin responsiveness ³⁶⁻³⁸. While most of experimental studies showing that UNx leads to glucose intolerance or has no impact on insulin sensitivity have been performed after a short starvation, the only metabolic study showing that UNx induced an insulin sensitivity in rats was performed after an overnight starvation. Our experiments are in line with the latest study as we have performed all our studies after an overnight starvation. Indeed our data unambiguously showed that UNx results in better insulin sensitivity and increase insulin-stimulated Akt signaling both in lean (liver and muscle) and obese mice (liver). Thus, it appeared that the starvation period prior metabolic studies is an important parameter to take into consideration. In addition, other parameters have to be considered such as glucose and insulin dose and route of administration, age, strain, sex of the animals and duration of post UNx analysed. Regarding clinical studies, parameters such as the cohort size, health condition and diet of kidney donors should also be considered.

The metabolic improvement observed in UNx mice can not be explained by a decrease of insulin clearance given that insulin levels were unaffected by UNx. However, we cannot rule out that the metabolic improvement observed after UNx, can be due to a 50% reduction of renal gluconeogenesis caused by the 50% reduction of kidney mass. Overall, our findings suggest an inter-organ communication between the kidney and insulin target tissues through a paracrine/endocrine factor not properly excreted in Unx animals. Thus, we hypothesized that FGF21 could be an interesting candidate for several reasons. First, FGF21 has been shown to be elevated in kidney donors ¹⁷. Secondly, FGF21 recently emerged as a beneficial factor in glucose and lipid metabolism ¹⁸⁻²¹. Lastly, FGF21 has been shown to be rapidly induced by fasting and mediates critical aspects of the adaptive response to starvation ³⁹. Thus differential FGF21 levels could explain the discrepancies between metabolic studies performed after different starvation periods. Because of all these reasons, the elevated serum FGF21 levels observed in UNx-operated animals could be responsible for the improvement of glucose metabolism and insulin sensitivity but more work is needed to confirm this hypothesis. Moreover our study showed the elevated FGF21 serum concentrations observed port UNx was not only due to a decrease in renal excretion as previously suggested but is also due to an increase of hepatic

FGF21 expression. Because of the increase hepatic FGF21 expression together with its receptor components in UNx-operated animals we can not exclude a potential development of a FGF21-resistant state over time (similarly to hyperinsulinaemia inducing insulin resistance).

In order to gain more understanding on the crosstalk between the kidney and insulin target tissues, we also explored the possible implication of the class II PI3K-C2 β isoform for several reasons. First, PI3K-C2 β gene expression has been found up-regulated in kidneys of diabetic nephropathy patients ²⁹. Second, this lipid kinase plays an important role in insulin signaling and it has been reported that its inactivation increased insulin sensitivity in mice ³⁰. Altogether, this suggested a potential role of PI3K-C2 β in the crosstalk between the kidney and insulin target tissues to regulate glucose metabolism in UNx context. One of the most remarkable findings of our study is the synergistic effect of the combination of UNx and PI3K-C2 β inactivation to protect against HFD-induced obesity and further potentiates the metabolic improvement observed in UNx alone. Our data suggested that the combination of UNx and PI3K-C2 β inactivation cooperatively play a positive role on FGF21 pathway through independent mechanisms with Unx mainly increasing serum FGF21 levels and PI3K-C2 β upregulating FGFR1 and β Klotho expression in liver and WAT leading to a synergistic upregulation of FGFR1 and β Klotho expression. This was accompanied with a synergistic enhancement of insulin-induced Akt phosphorylation in metabolic tissues.

We believe that our study has an important clinical relevance as it demonstrates a potential beneficial effect of living kidney donation to protect against metabolic disorders. However, this animal experimental study has certain limitations. First, UNx was performed on young (7 week-old) mice, whereas live donors are typically older than 30-years. Despite undergoing UNx at young age, we believe that our study has a long-term relevance as most of the analyses were performed 16 weeks post UNx, which is equivalent to 16 years post donation in human^{40, 41}. Secondly, while live kidney donors are in general both men and women, our study only used male mice. Based on the recent National Institutes of Health (NIH) guide notice to consider sex as a biological variable, we can therefore not generalise our study to female mice ^{42, 43}. Moreover, PI3K-C2 β inhibitor is not available yet. However, there is an increased interest in the development of specific PI3K-C2 β inhibitors with many pharmaceutical companies involved. Finally, our current study does not have any direct impact in the context of APOL1 high risk variants. Indeed, APOL1 high risk variants seen in patients of black ethnicity have been reported to confer risk of developing non diabetic kidney disease, hypertension and higher rate of end stage renal disease with no additive role in diabetic kidney disease (DKD) prevalence ^{44, 45}. Nevertheless, the APOL1 risk variants relationship to DKD still remain somehow mysterious. Indeed, obesity

that coexist with diabetes and induces glomerular injury, can complicate this relationship. Therefore, it would be interesting to assess in further studies the impact of PI3K-C2 β inactivation on APOL1 high risk variant-related diseases particularly in obesity condition. Moreover, our data suggests that even overweight patients or those with pre-diabetes could be safely used as potential kidney donors without subjecting them to increased risk of insulin resistance, type 2 diabetes and hepatic steatosis, increasing the number of potential kidney donors for transplantation. Furthermore, we identified PI3K-C2 β as a new therapeutic target for improving and preserving the health of kidney donors thus encouraging living kidney donation.

Acknowledgments

We are grateful to the members of all Diabetic Kidney Disease Centre group for support particularly to Dr. Steve Harwood for reading the manuscript. This work was directly funded by the Barts and the London National Institute of Health Research (NIHR) Cardiovascular Biomedical Research Unit. Support to SA, JEK, KM and MMY by the Barts Health “Diabetic Kidney Disease Centre,” funded by the Barts and the London Charity (Grant Number 577-2348).

Disclosure

The authors of this manuscript have conflicts of interest to disclose as described by the *American Journal of Transplantation*. B.V. is a consultant for Karus Therapeutics (Oxford, UK), iOnctura (Geneva, Switzerland) and Venthera (Palo Alto, CA, USA) and has received speaker fees from Gilead Sciences (Foster City, US). The other authors have no conflicts of interest to disclose.

Data Availability Statement

The data that supports the findings of this study are available in the supplementary material of this article.

Figure legends

Figure 1. Combination of UNx and PI3K-C2 β inactivation decreases HFD-induced obesity

(A) Changes in body weight of UNx and sham-operated mice fed a NCD or (B) HFD throughout the study. Body weight is expressed as a percentage of the basal starting at week 0 when UNx was performed. Area under the curve (AUC) is shown.

For all experiments shown, ≥ 6 mice/genotype/condition were used. Data represent mean \pm SEM. * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Figure 2. UNx and PI3K-C2 β inactivation synergistically protect against HFD-induced insulin resistance

(A) Serum glucose levels and (B) serum insulin levels under fasted conditions measured in both NCD (left panel) and HFD (right panel) conditions after overnight starvation.

(C) Glucose tolerance test after orally administration of 2g/kg of glucose in mice after overnight starvation under NCD and (D) HFD. AUC is shown.

(E) Insulin tolerance test after intraperitoneal injection of 0.75U/kg of insulin in mice after overnight starvation under NCD and (F) HFD. Glucose levels are expressed relative to the levels in mice of the same genotype before injection of insulin. AUC is shown.

For all experiments shown, 4-14 mice/genotype/condition were used. Data represent mean \pm SEM. * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

&: P value WT sham vs WT UNx; *: P value WT sham vs C2 $\beta^{D1212A/D1212A}$ sham; \$: P value WT sham vs C2 $\beta^{D1212A/D1212A}$ sham WT UNx; #: P value C2 $\beta^{D1212A/D1212A}$ sham vs C2 $\beta^{D1212A/D1212A}$ UNx; £: P value WT UNx vs C2 $\beta^{D1212A/D1212A}$ UNx .

Figure 3. UNx and PI3K-C2 β inactivation synergistically protect against HFD-induced liver steatosis

(A) Liver weight/body weight ratio of the indicated genotypes under both NCD (left) and HFD (right).

(B) Liver histology. Hematoxylin and eosin staining of liver sections of mice post UNx. Quantification of vacuolization of 7-9 livers/genotype/condition is shown on the right. a.u., arbitrary units. n.d., not detected.

Scale bar, 20 μ m.

(C) Liver triglyceride levels of 4-14 livers/genotype/conditions is shown.

(D) Liver homogenates isolated from overnight starved mice fed a HFD were analysed by SDS-PAGE and immunoblotting using the indicated antibodies. Each lane represents an individual mouse. 3-8 mice/genotype/condition were used.

Data represent mean \pm SEM. * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Figure 4. Combination of UNx and PI3K-C2 β inactivation increases FGF21 responsiveness

(A) Serum FGF21 levels under fasted conditions measured in both NCD and HFD conditions after overnight starvation. 5-15 mice/genotype/condition were used.

(B) Liver FGF21 mRNA expression. mRNA was extracted from overnight starved mice fed a HFD and was analysed by QPCR. 8-10 mice/genotype/condition were used

(C) Liver and WAT homogenates isolated from overnight starved mice fed a HFD were analysed by SDS-PAGE and immunoblotting using the indicated antibodies. Each lane represents an individual mouse. 3-8 mice/genotype/condition were used.

(D) Liver and WAT β klotho mRNA expression. mRNA was extracted from overnight starved mice fed a HFD and was analysed by QPCR. 4-9 mice/genotype/condition were used

Data represent mean \pm SEM. * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Figure 5. UNx and PI3K-C2 β inactivation synergistically enhance insulin-stimulated Akt signaling in metabolic tissues

(A-C) Tissue homogenates : liver, muscle and WAT, isolated from overnight starved mice fed a NCD or (D-F) HFD, 30 min after intraperitoneal injection of 0.75UI/kg insulin or PBS, were analysed by SDS-PAGE and immunoblotting using the indicated antibodies. Each lane represents an individual mouse. Quantification of the signals in tissues is shown on the right. WAT, white adipose tissue.

For all experiments shown, 3-9 mice/genotype/condition were used. Data represent mean \pm SEM. * $p < 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

References

1. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. *J Clin Invest.* Feb 1981;67(2):563-8. doi:10.1172/JCI110067
2. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. *Am J Physiol Renal Physiol.* Dec 1 2016;311(6):F1087-F1108. doi:10.1152/ajprenal.00340.2016
3. Chapagain A, Caton PW, Kieswich J, et al. Elevated hepatic 11beta-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. *Proc Natl Acad Sci U S A.* Mar 11 2014;111(10):3817-22. doi:10.1073/pnas.1312436111
4. Shehab-Eldin W, Zaki A, Gazareen S, Shoker A. Susceptibility to hyperglycemia in patients with chronic kidney disease. *Am J Nephrol.* 2009;29(5):406-13. doi:10.1159/000171379
5. de Boer IH, Zelnick L, Afkarian M, et al. Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD. *J Am Soc Nephrol.* 09 2016;27(9):2861-71. doi:10.1681/ASN.2015070756
6. Shehab-Eldin W, Shoeb S, Khamis S, Salah Y, Shoker A. Susceptibility to insulin resistance after kidney donation: a pilot observational study. *Am J Nephrol.* 2009;30(4):371-6. doi:10.1159/000232577
7. Ferreira-Filho SR, da Silva Passos L, Ribeiro MB. Corporeal weight gain and metabolic syndrome in living kidney donors after nephrectomy. *Transplant Proc.* Mar 2007;39(2):403-6. doi:10.1016/j.transproceed.2007.01.028
8. Jepson C, Hsu JY, Fischer MJ, et al. Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *Am J Kidney Dis.* Sep 1 2018;doi:10.1053/j.ajkd.2018.06.017
9. Sui Y, Zhao HL, Ma RC, et al. Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. *Cell Mol Life Sci.* Dec 2007;64(23):3119-28. doi:10.1007/s00018-007-7395-1
10. Zhao HL, Sui Y, Guan J, et al. Fat redistribution and adipocyte transformation in uninephrectomized rats. *Kidney Int.* Aug 2008;74(4):467-77. doi:10.1038/ki.2008.195
11. Ibrahim HN, Berglund DM, Jackson S, Vock DM, Foley RN, Matas AJ. Renal Consequences of Diabetes After Kidney Donation. *Am J Transplant.* Dec 2017;17(12):3141-3148. doi:10.1111/ajt.14416
12. Keys DO, Jackson S, Matas AJ. Kidney Donor Outcomes \geq 50 Years after Donation. *Clin Transplant.* Jul 8 2019;doi:10.1111/ctr.13657

13. O'Keefe LM, Ramond A, Oliver-Williams C, et al. Mid- and Long-Term Health Risks in Living Kidney Donors: A Systematic Review and Meta-analysis. *Ann Intern Med*. Feb 20 2018;168(4):276-284. doi:10.7326/M17-1235
14. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. *N Engl J Med*. Jan 2009;360(5):459-69. doi:10.1056/NEJMoa0804883
15. Kato Y, Ohno Y, Hayashi M, et al. Divergent effects of unilateral and subtotal nephrectomy on insulin sensitivity in rats. *Ren Fail*. 2005;27(4):451-7.
16. Chin SH, Item F, Wueest S, et al. Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice. *Diabetes*. Apr 2015;64(4):1131-41. doi:10.2337/db14-0779
17. Hindricks J, Ebert T, Bachmann A, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. *Clin Endocrinol (Oxf)*. Jun 2014;80(6):918-24. doi:10.1111/cen.12380
18. Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Haring HU. Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. *Endocr Rev*. Oct 1 2017;38(5):468-488. doi:10.1210/er.2017-00016
19. Kharitonov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. *J Clin Invest*. Jun 2005;115(6):1627-35. doi:10.1172/JCI23606
20. Kharitonov A, DiMarchi R. Fibroblast growth factor 21 night watch: advances and uncertainties in the field. *J Intern Med*. Mar 2017;281(3):233-246. doi:10.1111/joim.12580
21. Tezze C, Romanello V, Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. *Front Physiol*. 2019;10:419. doi:10.3389/fphys.2019.00419
22. Jimenez V, Jambrija C, Casana E, et al. FGF21 gene therapy as treatment for obesity and insulin resistance. *EMBO Mol Med*. Aug 2018;10(8)doi:10.15252/emmm.201708791
23. Berglund ED, Li CY, Bina HA, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. *Endocrinology*. Sep 2009;150(9):4084-93. doi:10.1210/en.2009-0221
24. Yu D, Ye X, Wu Q, et al. Insulin sensitizes FGF21 in glucose and lipid metabolisms via activating common AKT pathway. *Endocrine*. Jun 2016;52(3):527-40. doi:10.1007/s12020-015-0801-9
25. Emanuelli B, Vienberg SG, Smyth G, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. *J Clin Invest*. Feb 2014;124(2):515-27. doi:10.1172/JCI67353
26. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. *Endocrinology*. Jan 2012;153(1):69-80. doi:10.1210/en.2010-1262

27. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. *Diabetes Care*. Aug 2009;32(8):1542-6. doi:10.2337/dc09-0684
28. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. *Diabetes*. Nov 2010;59(11):2781-9. doi:10.2337/db10-0193
29. Wilson PC, Wu H, Kirita Y, et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. *Proc Natl Acad Sci U S A*. 09 2019;116(39):19619-19625. doi:10.1073/pnas.1908706116
30. Alliouachene S, Bilanges B, Chicanne G, et al. Inactivation of the Class II PI3K-C2beta Potentiates Insulin Signaling and Sensitivity. *Cell Rep*. Dec 1 2015;13(9):1881-94. doi:10.1016/j.celrep.2015.10.052
31. Musso G, Cassader M, Cohny S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. *Trends Mol Med*. Oct 2015;21(10):645-662. doi:10.1016/j.molmed.2015.08.005
32. Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. *Int J Mol Sci*. Apr 2016;17(4):562. doi:10.3390/ijms17040562
33. Musso G, Cassader M, Cohny S, et al. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. *Diabetes Care*. Oct 2016;39(10):1830-45. doi:10.2337/dc15-1182
34. Orsic V, Mihalj M, Mogus M, et al. Impaired kidney function in rats six months after unilateral nephrectomy - an old story, a new perspective. *Med Glas (Zenica)*. Aug 2011;8(2):185-91.
35. Hayslett JP. Functional adaptation to reduction in renal mass. *Physiol Rev*. Jan 1979;59(1):137-64. doi:10.1152/physrev.1979.59.1.137
36. Chen W, Zhou H, Saha P, Li L, Chan L. Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bsl2/Seipin-deficient mice. *Endocrinology*. Nov 2014;155(11):4215-25. doi:10.1210/en.2014-1292
37. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. *Am J Physiol Endocrinol Metab*. Dec 2008;295(6):E1323-32. doi:10.1152/ajpendo.90617.2008
38. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. *Diabetes*. Feb 2006;55(2):390-7. doi:10.2337/diabetes.55.02.06.db05-0686
39. Fazeli PK, Lun M, Kim SM, et al. FGF21 and the late adaptive response to starvation in humans. *J Clin Invest*. Nov 2015;125(12):4601-11. doi:10.1172/JCI83349


40. Zhang H, Lin S, Chen X, et al. The effect of age, sex and strains on the performance and outcome in animal models of stroke. *Neurochem Int.* 07 2019;127:2-11. doi:10.1016/j.neuint.2018.10.005
41. Flurkey K CJ, Harrison DE. the Mouse in Aging Research. *The Mouse in Biomedical Research.* Elsevier; 2007:637-672:chap 20.
42. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. *Nature.* May 2014;509(7500):282-3. doi:10.1038/509282a
43. Mauvais-Jarvis F, Arnold AP, Reue K. A Guide for the Design of Pre-clinical Studies on Sex Differences in Metabolism. *Cell Metab.* Jun 2017;25(6):1216-1230. doi:10.1016/j.cmet.2017.04.033
44. Waitzman JS, Wilkins JT, Lin J. Sends Its REGARDS to Cardiovascular Disease. *Circ Genom Precis Med.* 06 2018;11(6):e002212. doi:10.1161/CIRCGEN.118.002212
45. Friedman DJ, Pollak MR. APOL1 Nephropathy: From Genetics to Clinical Applications. *Clin J Am Soc Nephrol.* Jul 2020;doi:10.2215/CJN.15161219

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure 1

A



B






Figure 2


A




C




E



B



D



F






Figure 3


A



B



C



D






Figure 4


A



B



C



D






Figure 5


A




B




C



D



E



F

